Related Experiment Video
Updated: Feb 1, 2026

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
Published on: September 10, 2014
Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines
Karolina Sterzyńska1, Andrzej Klejewski2,3, Karolina Wojtowicz1
1Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland.
Abstract:
Background: Low effectiveness of chemotherapy in ovarian cancer results from development of drug resistance during treatment. Topotecan (TOP) is a chemotherapeutic drug used in second-line chemotherapy of this cancer. Unfortunately, during treatment cancer can develop diverse cellular and tissue specific mechanisms of resistance to cytotoxic drugs. Methods: We analyzed development of TOP resistance in ovarian cancer cell lines (A2780 and W1). On the base of our previous results where a set of "new genes" with different functions that can be related to TOP-resistance was described hereby we performed detailed analysis of MYOT expression. MYOT mRNA level (real time PCR analysis), protein expression in cell lysates and cell culture medium (western blot analysis) and protein expression in cancer cells (immunofluorescence analysis) were determined in this study. Results: We observed increased expression of MYOT in TOP resistant cell lines at both mRNA and protein level. MYOT, together with extracellular matrix molecules like COL1A2 and COL15A1 were also secreted to corresponding cell culture media. Conclusion: Our results suggest that upregulation of MYOT can be related to TOP resistance in ovarian cancer cell lines.
Insights
Drug resistance limits chemotherapy effectiveness in ovarian cancer. This study found increased MYOT expression in topotecan-resistant ovarian cancer cells, suggesting a link to treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Chemotherapy in ovarian cancer faces challenges due to acquired drug resistance.
- Topotecan (TOP) is a key drug in second-line ovarian cancer treatment, but resistance limits its efficacy.
- Cancer cells develop diverse resistance mechanisms, impacting treatment outcomes.
Purpose of the Study:
- To investigate the role of MYOT expression in the development of topotecan resistance in ovarian cancer.
- To analyze MYOT mRNA and protein levels in topotecan-resistant ovarian cancer cell lines.
Main Methods:
- Analysis of MYOT messenger RNA (mRNA) levels using real-time PCR.
- Assessment of MYOT protein expression in cell lysates and culture media via western blot.
- Immunofluorescence analysis to determine MYOT protein localization in cancer cells.
Main Results:
- Elevated MYOT expression was observed at both mRNA and protein levels in topotecan-resistant ovarian cancer cell lines.
- MYOT, along with extracellular matrix proteins COL1A2 and COL15A1, was detected in cell culture media.
- Increased MYOT expression correlates with topotecan resistance in ovarian cancer models.
Conclusions:
- Upregulation of MYOT is associated with topotecan resistance in ovarian cancer.
- MYOT may play a role in the mechanisms underlying chemoresistance in ovarian cancer.
Related Concept Videos
Treatment Resistant Cancers
Cell Lines
Lossless Lines
Resistivity
Resistance
Ovarian Cycle

